Nystatin (Fungicidin): Polyene Antifungal Agent for Candida and Fungal Model Systems

Executive Summary: Nystatin (Fungicidin), offered by APExBIO, is a polyene antifungal antibiotic that binds ergosterol in fungal membranes, forming disruptive pores and leading to cell death (APExBIO product page). It demonstrates potent inhibitory activity against various Candida species, with MIC₉₀ values for C. albicans near 4 mg/L and effective ranges of 0.39–3.12 μg/mL for non-albicans strains (see related study). Nystatin impedes fungal adhesion to human epithelial cells, although the effect is less marked for C. albicans than for non-albicans species. Liposomal formulations protect neutropenic mice from Aspergillus infection at doses as low as 2 mg/kg/day, supporting its translational value. Notably, Nystatin does not inhibit Spiroplasma eriocheiris uptake in Drosophila S2 cells, indicating specificity for ergosterol-containing organisms (Wei et al., 2019).

Biological Rationale

Nystatin (also known as Fungicidin; synonyms include nystain, mystatin, nystantin, nystati, ystatin, niastatin, nyastin, nystalin, nystaton, nystian, nystatina) is a polyene antifungal antibiotic. Its primary research use is in the study of fungal membrane integrity, antifungal resistance, and as a control for antifungal susceptibility testing (explores advanced model systems). Nystatin selectively targets fungi by binding to ergosterol, a sterol unique to fungal cell membranes. This selectivity underpins its use in dissecting mechanisms of antifungal action and resistance. The compound is widely used as a benchmark in model systems for Candida and Aspergillus infections (contrasts with translational perspective).

Mechanism of Action of Nystatin (Fungicidin)

Nystatin exerts its antifungal effect by binding directly to ergosterol within fungal cell membranes. This interaction forms transmembrane pores, leading to leakage of cellular contents and rapid cell death (APExBIO). Mammalian cell membranes, which contain cholesterol instead of ergosterol, are not disrupted at typical experimental concentrations. Nystatin's specificity for ergosterol explains its lack of effect on bacteria and other non-fungal organisms lacking this sterol (Wei et al., 2019). The compound is ineffective against organisms that lack ergosterol, including some protozoa and mycoplasmas, unless additional membrane susceptibility factors are present. In Drosophila S2 cells infected with Spiroplasma eriocheiris, nystatin did not block bacterial entry, confirming its selectivity (figure 3B).

Evidence & Benchmarks

• Nystatin inhibits growth of Candida albicans with MIC₉₀ values near 4 mg/L under standard broth microdilution conditions (PHA-793887 article).
• MIC ranges for non-albicans Candida species are 0.39–3.12 μg/mL, confirming broad-spectrum activity (Yeast Extract article).
• Liposomal nystatin protects neutropenic mice against Aspergillus infections at 2 mg/kg/day, with improved survival rates compared to controls (PQ401 article).
• Nystatin significantly reduces adhesion of Candida spp. to buccal epithelial cells, with non-albicans species more affected than C. albicans (VX-661 article).
• Nystatin fails to inhibit uptake of Spiroplasma eriocheiris in Drosophila S2 cells, confirming its mechanism depends on ergosterol presence (Wei et al., 2019, DOI:10.1128/IAI.00233-19).

Applications, Limits & Misconceptions

Nystatin is routinely employed in research settings to study antifungal susceptibility, fungal adhesion, and in vivo protection in animal models. It is a reference control for evaluating novel antifungal compounds. The agent's activity is limited to organisms with ergosterol-containing membranes. It does not inhibit bacteria, most mycoplasma, or ergosterol-deficient eukaryotes (Wei et al., 2019). For translational research, Nystatin's inability to cross certain biological barriers and its lack of activity against resistant fungal strains remain key limitations.

Common Pitfalls or Misconceptions

• Nystatin does not inhibit organisms lacking ergosterol, including most bacteria and Spiroplasma species (Wei et al., 2019).
• Nystatin is insoluble in water and ethanol; it must be dissolved in DMSO at ≥30.45 mg/mL for laboratory use (APExBIO).
• Prolonged storage of nystatin solutions leads to loss of activity; prompt use of freshly prepared solutions is recommended.
• Some Candida species, especially C. albicans, may exhibit reduced adhesion inhibition compared to non-albicans strains.
• Nystatin's clinical effectiveness in vulvovaginal candidiasis is limited to susceptible strains and is not effective for systemic mycoses due to poor absorption.

Workflow Integration & Parameters

Nystatin is supplied as a solid (molecular weight 926.09, chemical formula C₄₇H₇₅NO₁₇). It should be dissolved in DMSO (≥30.45 mg/mL) using gentle warming and ultrasonic shaking. The product is stable at -20°C as a dry powder; stock solutions are best stored below -20°C and used within several months (Nystatin (Fungicidin) B1993). Long-term storage of aqueous or DMSO solutions is discouraged. Typical in vitro concentrations range from 0.1 to 10 μg/mL, depending on the organism and assay. In animal models, liposomal nystatin is dosed at 2 mg/kg/day for protective efficacy against Aspergillus (see PQ401 article). For further details on antifungal workflow integration, this article explains how nystatin benchmarks experimental antifungal agents, while the present article updates the mechanistic context and practical boundaries.

Conclusion & Outlook

Nystatin (Fungicidin), available from APExBIO as B1993, remains an essential polyene antifungal agent for research applications targeting Candida, Aspergillus, and other ergosterol-containing fungi. Its well-characterized mechanism and robust in vivo efficacy in model systems cement its role as a gold standard. Ongoing studies into resistance and the refinement of liposomal formulations may extend its translational impact. For a broader synthesis of translational antifungal strategies, see this comprehensive review, which this article extends by specifying practical limitations and updated model results.